This analysis quantifies the epidemiologic and economic burden of pneumococcal disease attributable to 15-valent pneumococcal conjugate vaccine (PCV15) serotypes in a hypothetical cohort of US adults aged 65 years and older in the US.
A Markov model was used to estimate pneumococcal disease cases, deaths and costs attributable to PCV15 serotypes. A cohort of unvaccinated adults aged ≥65 years from 2017 were tracked until death. Economic burden was estimated from a payer perspective, by multiplying the number of inpatient/outpatient visits by the cost per inpatient/outpatient visits. Costs were discounted at 3% per year.
An estimated 74,956 cases of IPD; 10,336 cases of IPD related deaths; 2,286,581 cases of NBPP hospitalizations and 135,566 cases of NBPP related deaths were attributable to PCV15 serotypes in adults aged ≥65 years in the U.S. Total lifetime discounted healthcare costs attributable to PCV15 serotypes were estimated to be approximately $19.9 million. 36.3% of these cases, deaths and costs were attributable to serotypes 22F and 33F and 42.4% were attributable to serotype 3.
PCV15 serotypes contribute to substantial health and economic burden of pneumococcal disease among older adults (aged ≥65 years) in the U.S., majority of which is attributable to the serotypes 3, 22F, and 33F.